ArticleScientific reports2026
Generation of a novel Dysferlin microdeletion knock-in mouse model mimicking muscular dystrophy-like pathology.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Limb-Girdle Muscular Dystrophy type R2 (LGMD-R2) is caused by mutations in the DYSFERLIN (DYSF) gene, leading to progressive muscle weakness and defective membrane repair. In our previous study, we identified a novel five-nucleotide microdeletion in DYSF (c.3014_3018delACCAG; NM_001130455.2) in Taiwanese LGMD patients, which is predicted to cause a frameshift and premature termination, potentially producing a truncated ~ 108 kDa dysferlin protein. To investigate its pathogenic consequences in vivo, we generated a Dysf microdeletion knock-in mouse model (DysfΔ5/Δ5) to recapitulate the patient-relevant genetic lesion and associated muscular dystrophy–like phenotypes. DysfΔ5/Δ5 mice exhibited undetectable dysferlin expression, impaired rotarod performance, and progressive pathological changes, including increased centrally nucleated fibers, and adipocyte infiltration within skeletal muscle tissues. Immunostaining of muscle tissues revealed disrupted sarcoglycan localization; furthermore, a trend toward macrophage accumulation was observed. Proteomic profiling quantified 2,329 proteins in skeletal muscle from DysfΔ5/Δ5 and wild-type mice, revealing a remodeling proteomic signature in DysfΔ5/Δ5 muscle. Gene Ontology enrichment highlighted lipid catabolic/metabolic processes alongside reduced representation of muscle development, sarcomeric organization, and contractile programs, consistent with dystrophic remodeling and fatty/fibrotic replacement. Together, these results indicate that Dysf Δ5/Δ5 mice exhibit muscular dystrophy–like pathological and functional features consistent with dysferlinopathy, providing a useful platform for mechanistic investigation and preclinical proof-of-concept studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.